CATX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Perspective Therapeutics Inc (CATX) is not a strong buy at this time for a beginner investor with a long-term horizon. While the stock has potential upside based on analyst ratings and price targets, the lack of recent positive news, weak financial performance, and bearish technical indicators suggest waiting for a more favorable entry point.
The technical indicators are mixed to bearish. The MACD is negative and expanding downward, indicating bearish momentum. The RSI is neutral at 44.182, showing no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below the pivot level of 5.389, with key support at 5.011. The stock has a 40% chance of gaining 2.01% in the next day, but the overall trend lacks strong bullish confirmation.
The company has a promising pipeline of lead-212 radiotherapies, and a competitor's deprioritization of a similar product is a favorable development.
The MACD and RSI do not indicate strong bullish momentum, and the stock is trading below key pivot levels.
In Q3 2025, revenue dropped by 43.36% YoY to $209,000. However, net income improved by 71.73% YoY to -$25.97M, and EPS increased by 66.67% YoY to -0.35. Gross margin remained stable at 100%. Despite some improvements in profitability metrics, the overall financial performance remains weak.
Analysts are bullish on the stock, with Piper Sandler assigning an Overweight rating and a $16 price target, and H.C. Wainwright raising the price target to $12. Near-term catalysts are expected in mid-2026, but these are not immediate drivers for the stock.
